





Epilepsy/seizure disorder is the most common childhood neurologic condition. Antiepileptic drugs (AEDs) are the mainstay of 
epilepsy treatment. Ketogenic diet (KD) is an effective dietary therapy for children with intractable epilepsy. However, both 
these two therapy increase risk of vitamin and mineral deficiency and may cause osteoporosis in children. I report the case of a 
7-year-old girl presented with a 2-day history of vomiting and increased seizures activity to three times per week. Her past 
medical history is remarkable for epilepsy and has been on multiple AEDs since age 16 month. The 3:1 ratio KD was started 
from age 3 with a moderate improvement in seizure activity from weekly episode to monthly. To enhance the effect of ketosis 
on seizure control, she was put on 4:1 ration KD with gradual improvement. Bone density scan (DEXA scan) shows worsening 
bone mineral density through the past year possibly due to immobility and long term AEDs and KD uses.  Calcium and vitamin D 
supplement together with adequate energy intake is important to manage her osteoporosis and promote optimal growth.  
INTRODUCTION: 
Epilepsy/seizure disorder is the most common childhood neurologic condition,1 and a major public health concern.2 In a 
nationally representative sample of US children, estimated prevalence of reported lifetime epilepsy/seizure disorder was 1%, 
and of current epilepsy/seizure disorder was 6.3/1000.3 Children diagnosed with epilepsy face considerable physical, 
educational and emotional challenges. The seizures themselves, especially when poorly controlled, may be disabling and 
interfere with the child’s ability to learn and developmental progress including attention-deficient hyperactivity disorder (ADHD) 
4,5,6 and learning disabilities.7,8,9 Antiepileptic drugs (AEDs) remain the mainstay of treatment for epilepsy. However, both 
epilepsy and AEDs are associated with adverse effects on bone health. Children with epilepsy treated with AEDs are at an 
increased risk of fractures due to seizure itself and decreased bone mineral density (BMD) 10 from AEDs.11 Antiepileptic drugs 
can adversely affect bone health by directly affecting the cells of bone formation and absorption or by secondary effects on 
calcium and vitamin D metabolism.12  
 
The ketogenic diet, a high-fat, low-carbohydrate, and protein diet, is an effective non-pharmacologic therapy for children with 
intractable epilepsy. 13,14,15 The classic ketogenic diet contains a 4:1 ratio by weight of fat to combined protein and 
carbohydrate (90% of calories from fat). Studies show that the number and severity of seizures may decrease for more than 




AEDs.18 This high-fat, low-carbohydrate diet stimulates a ketogenic process that forces the body to use ketone bodies as the 
new source of energy.  The mechanism whereby ketosis limits seizures is not well understood. Various theories19 have  
postulated that: 1) there is a direct stabilizing effect of ketone bodies on the central nervous system; 2) the acidosis due to 
ketosis modifies the seizure threshold; 3) changes in fluid and electrolyte balance mitigate seizures; and 4) change in lipid 
concentration induced by the diet has an antiseizure effect.  
 
Medline searches were performed using the keywords epilepsy cross-referenced with the textwords ketogenic diet and 
controlled trial. In total, 53 articles were retrieved, describing 21 clinical trials, 19 review studies with 4 systematic reviews, 3 
case reports, and 10 other articles. Of the 21 clinical trials, 16 studies met the inclusion criteria for detailed review. Inclusion 
criteria are 1) reported relevant health outcomes after treatment with the ketogenic diet in children with refractory epilepsy 
(refractory was defined as suboptimal control of seizures despite multiple medication trials or intolerance to any effective 
medications); and 2) treatment given was either the classic 4:1 ketogenic diet or a modification of this diet (eg, , 3:1 ketogenic 
diet, medium chain triglyceride diet, modified Atkin diet). Study characteristics are presented in Table 1.  
 
The main outcome measure evaluated is a reduction in seizure frequency. The optimal outcome is complete elimination of 
seizures. A 50% or greater reduction in seizures is considered clinically significant. Many studies also reported the percentage of 
patients achieving near complete elimination of seizures, usually with a reduction of 90% or more. These 3 outcome measures 
(complete elimination of seizure, 90% reduction in seizures, and 50% reduction in seizures) are the outcomes that are reported 
in this review. Outcomes and conclusions of the 16 studies are presented in Table 2.  
 
The body of evidence consists of all controlled studies of children treated on ketogenic diet published between 1998 and 2011. 
Children with epilepsy treated in these studies were initially refractory to treatment with AEDs. All studies were full-length 
articles published in peer-reviewed journals.20-35  Nine of the 16 published studies were randomized clinical trials with 12 days 
to 1 year study duration.
20,21,23,24,25,27-30
 Six studies reported seizure-free outcome with percentages ranged from 6-84%. 
20,22, 
23,28,30,31,32 The results of these studies are consistent in showing that some children benefit from the ketogenic diet, 










Table 1: Clinical trials on KD in the treatment of refractory seizures – Study Characteristics  
Study, year Patients Age 
(years) 
Diet type Study Design Study Duration 
Raju et al., 2011 38 children with refractory 
epilepsy 
0 - 5  2.5:1 vs 4:1 KD Randomized 3 months 
Christodoulides , 
2011 
91 children on classical or 
MCT KD 
2-16  MCT vs 4:1 KD  Randomized 
Pairing 
12 months 
Nabbout  et al., 2011 15 children with Dravet 
syndrome 
4-11 non specified KD Prospective 12 months 
Kang et al., 2011 40 children with 
intractable epilepsy 
1-18  3:1 KD Randomized 8 months  
vs 2 years  
Neal et al., 2009 145 children with 
intractable epilepsy 
2-16 MCT vs 4:1 KD  Randomized 12 months 
Freeman et al., 2009 20 children with 
intractable Lennox-
Gastaut syndrome  
1-7 3:1 or 4:1 KD Randomized  
Crossover 
12 days 
Nizamuddin , 2008 137 children with 
inctractable epilepsy 
0-14 3:1 or 4:1 KD Prospective 4 years 
Neal et al., 2008 145 children with daily 
seizure 
2-16 3:1 or 4:1 KD Randomized 
Controlled  
3 months 
Seo et al., 2007 76 children with refratory 
seizure 
0-16 3:1 vs 4:1 KD Randomized 3 months 
Kossoff  et al., 2007 20 children with daily 
seizure 
3-16 modified Atkin diet:           
10g CHO vs 20g CHO 
Randomized 6 months 
Bergqvist et al., 2005 48 children with 
intractable seizure 
1-14 4:1 KD:                              
fasting(FAS-KD) vs 
gradual 





Klepper et al., 2005 15 children with GLUT1 
deficiency syndrome 
5-12 3:1 KD Prospective 5.5 years 
Kim et al., 2004 124 children with 
intractable seizure 
2-7 4:1 KD:                        
nonfasting (NFKD) vs 
initial fasting(IFKD) 
Retrospective 3 months 
Liu, 2003 25 children with complex 
epilepsy 
1-16y 4:1 vs MCT KD Prospective 4 months 




4:1 KD:                             




Vining et al., 1998 51 children with 
intractable seizure 








Table 2:  Clinical trials on KD in the treatment of refractory seizures – Study outcomes and Conclusions 





Raju et al., 2011 26% in the 4:1 
group ,21% in 2.5:1 
group 
NR 58% in 4:1 group              
63% in 2.5:1 group 
 2.5:1 KD is as effective as 4:1 KD in 
controlling seizures with fewer adverse 
effects. 
Christodoulides , 2011 NR NR NR Decrease in plasma vitamins A 
and E and  magnesium status 
after 12 months.  
Micronutrient status may be suboptimal in 
4:1 KD group. 
Nabbout et al., 2011 6% NR NR 40% patients decrease seizure> 
75% at 9months 
KD might have a double effect, on seizure 
control and hyperactivity and behavior 
disturbances in patients with Dravet 
syndrome. 
Kang et al., 2011 81% in 8 month group, 
84% in 2 years group 
NR NR Significant growth failure was 
complicated only in KD > 2 years 
group.  
8 months of KD have similar outcome, 
recurrence rate, and less growth 
disturbance than 2 years KD.  
Neal et al., 2009 NR 9.6% in 4:1 KD 
group,  9.7% in 
MCT diet 
group 
17.8% in 4:1 KD 
group, 22.2% in MCT 
diet group 
Serum acetoacetate and 
b-hydroxybutyrate levels at 3 
and 6 months were significantly 
higher in children on 4:1 KD. 





Freeman et al., 2009 NR NR NR No reduction of EGG events in 
both groups. 
Glucose or saccharin solution with KD is not 
effective in reducing seizure frequency. 
Nizamuddin , 2008 NR NR NR Children receiving a solely 
formula-based KD were less 
likely to have 
hypercholesterolemia than solid 
food KD. 
Hypercholesterolemia occurs in most 
children receiving solid food KD but 
improved in half, even without 
interventions. 
Neal et al., 2008 NR 7% in diet 
group , 0% in 
control group  
38% in diet group              
6% in control group  
Support KD in treating children with 
intractable epilepsy. 
Seo et al., 2007 55% in 4:1 group       
30.5% in 3:1 group 
5% in 4:1 
group, 5.6% in 
3:1 group 
25% in 4:1 group             
36% in 3:1 group 
Dietary tolerability was better in 
3:1 diet than 4:1 with less GI 
symptoms. 
The 4:1 KD showed greater antiepileptic 
efficacy than 3:1 diet with higher seizure-
free outcome. 
Kossoff et al., 2007 NR 30% in 10g 
CHO group, 
40% in 20g 
CHO group 
50% in 10g CHO 
group, 50% in 20g 
CHO group 
Most parents reported no 
change in seizure frequency or 
ketosis between groups, but 
improved tolerability with 20 g 
per day. 
Carbohydrate limit of 10 g per day for 
children starting the modified Atkins diet 
may be ideal, with a planned increase to a 
more tolerable 20 g per day after 3 months. 
Bergqvist et al., 2005 21% in FAS-KD group 
21% in GRAD-KD group 
29% in FAS-KD 
group, 46% in 
GRAD-KD 
58% in FAS-KD group           
67% in GRAD-KD 
group 
Children in GRAD-KD lost less 
weight, had fewer episodes of 
hypoglycemia, acidosis and 
GRAD-KD results in fewer adverse events 





group dehydration.  
Klepper et al., 2005 66% NR NR 13% patients seizures recurred 
after 2½ years despite adequate 
ketosis 
GLUT1 deficiency syndrome can be treated 
effectively by ketogenic diet. 
Kim et al., 2004 34.1% in NFKD group, 
34.9% in IFKD group 
19.5% in NFKD 
group, 18.1% 
in IFKD group 
22% in NFKD group           
22.9% in IFKD group 
No difference in hypoglycemia 
events between both groups. 
Shortening hospital stay in NFKD 
group because less dehydration. 
Initial fasting and fluid restriction are not 
essential for the KD. 
Liu, 2003 NR NR NR Both groups did not have 
significant increases in 
height/age %ile with weight %ile 
decreased by 10%ile for both 
diets. Nutrient intakes from the 
diet and vitamin and mineral 
supplements met DRI. 
For children on KD, recommend adequate 
intake of energy and protein, a higher 
proportion of unsaturated to saturated 
dietary fats, and consider vitamin and 
mineral supplements. 
John M. Freeman et al., 
1999 
NR NR 100% in both groups  It is feasible to evaluate KD in blinded 
crossover study.  
Vining et al., 1998 NR 22% 18%  KD is effective in intractable epilepsy and 






A 7-year-old girl presented with a recent 2-day history of vomiting and increased seizure frequency. Mother and grandmother 
described the seizure activities as in her left leg and both hands. Her seizure frequency increased from one episode per month 
to three times in the past one week before admission. She has two types of seizure and there is no change in her monthly tonic-
clonic seizure with whole body stiffening up, turning blue, and eyes going back in her head.  Her past medical history is 
remarkable for congenital CMV infection, microcephaly, static encephalopathy, infantile cerebral palsy, developmental delay, 
epilepsy since age 16 month, and GERD status post Nissen and G tube placement since age 3. At age 4, she started to 
experience weekly seizures while on 2 different AEDs (carbamazepine and zonisamide). Because of her poor response to 
medication therapy, KD was started with a 3:1 ratio. The acidotic state was confirmed by the presence of urine ketones in 
moderate amounts. Three weeks after the initiation of KD, the frequency of seizures decreased from weekly to monthly. She 
tolerated 3:1 KD with no problems and has been on it from age 4 until now.  
During this admission, head CT was negative for acute infarct of hemorrhage. Brain MRI finding was consistent with congenital 
CMV infection without acute process. Lab studies showed urine ketones were constantly in the moderate range. vEEG was 
suggestive of severe diffuse encephalopathy with partial/multifocal seizure onset. Blood carbamazepine level at 3.3 mcg/mL 
and carbamazepine was discontinued. She was maintained at the same dose of zonisamide and increased levetiracetam to     
500 mg BID. KD was modified from 3:1 ratio to 4:1 in light of the increased seizure activity per vEEG and clinical presentation. 
No seizure activity was reported during her three days in hospital and she was discharged with zonisamide, levetiracetam, 
diazepam, and KetoCal 4:1 formula.  After discharge, her seizure has decreased from three times per week to weekly. She is 
currently followed up as outpatient at pediatric neurology clinic to fine tuning AEDs and KD for further decreasing seizure 
frequency.  
One month before this admission, her bone density scan (DEXA scan) showed very low bone mineral density with a Z-score of -
4.6 at the lumbar spine. Bone density had decreased 19% over the past year despite the use of calcium and vitamin D 
supplements. No fractures were detected radiographically and there was no history of fracture. During this admission, another 
DEXA scan showed that the Z score had further decreased to -6.7 (Table1). The low Z score (under 2.0) confirms that the patient 





Table 3: DEXA scan Z score from July 2012 to Aug 2013. 
 2012.7 2013.7 2013.8 
DEXA scan Z score -3.9 -4.6 -6.7 
 
Laboratory studies showed blood calcium of 9.3 mg/dL and phosphorus of 5.4 mg/dL. PTH was found to be low at 8 pg/ml. 
Because of concerns regarding the diet adequacy in minerals and micronutrients, I reviewed her diet history and assessed her 
average intake of key nutrients.  Her daily intake consisted of two meals with 300 kcal each and KetoCal 4:1 formula at 60ml/hr 
for 10 hours through G tube at night. This provides her 1500 kcal per day and meets 100% of energy needs. Intake estimates 
are presented in Table4. All intake analysis was performed by NutritionCalc Plus 3.0 except for vitamin K. National Nutrient 
Database for Standard Reference data were used for vitamin K estimates. Graph 1 presents the comparison between DRI and 
nutrient intakes in calcium, phosphorus, vitamin D, and vitamin K.   
Table 4: Intake estimates on vitamin A, C, D, E, K, and calcium, phosphorus, iron, zinc, selenium    
 DRI  Dietary Intake EN(KetoCal 4:1) Supplement 
Vitamin A (µg) 400 384.2 214.6 1057 
Vitamin C (mg) 25 21.48 25.2 69.6 
Vitamin D (IU) 200 28 120 800 
Vitamin E (mg) 7 3.97 4.176 20.3 
Vitamin K (µg) 55 42.6 15.3 32.9 
Calcium (mg) 800 76.8 464 800 
Phosphorus (mg) 500 112.3 377 270 
Iron (mg) 10 1.29 4.1 20.3 
Zinc (mg) 5 0.98 3.3 11.1 







Graph 1: Comparing dietary intake, KetoCal, and supplement with DRI on calcium, phosphorus, vitamin D, and vitamin K.   
 
DISCUSSION:  
In this case report I describe the management of otherwise intractable epilepsy in a 7 year old child with AEDs and KD, and the 
development osteoporosis. Since she was 16 month old, this patient was reported to be on multiple AEDs with weekly to 
monthly seizures activity. Her seizure was stable with only monthly episodes after initiating 3:1 ratio KD after age 4. Comparing 
the efficacy of 3:1 to 4:1 ratio KD in refractory epilepsy shows mixed results. 20,28 The patient tolerated 4:1 ratio KD with urine 
ketone-control within moderate range during admission. The initial response is acceptable, but continuous follow-up will be 
necessary to evaluate the long-term efficacy of such a strict KD regimen. 
Promoting growth is a challenge for children on KD. The 4:1 ratio KD provides less than 10% of protein which is not enough to 
support children’s growth. One study shows that weight-for-age percentile decreased in children on 4:1 ratio KD with no 
change in stature-for-age percentile on CDC growth chart. 
34
 Although this patient grows proportionally with BMI-for-age at 50
th
 
percentile, her weight-for-age and stature-for-age has been stayed on 3rd percentile since age 4. The adequacy of 4:1 KD on key 
nutrients has been studied in one clinical trial and showed decreased plasma vitamin A and selenium level.21 This patient 
received 264% of DRI in vitamin A and 185% in selenium through supplements. Supplements like multi vitamin are important 
source for key micronutrients for children on 4:1 KD. By ensuring adequate intake of energy, the goal for nutrition intervention 



















After the diagnosis of osteoporosis, there were concerns regarding the simultaneous use of AEDs and KD because of the risk of 
further decreasing bone density. Progressive loss of bone mineral content can be seen in children on KD with intractable 
epilepsy, particularly for younger non ambulatory children with low BMI status. 30 The mechanism is unclear and few studies 
focused on the effect of KD on mineral and vitamins. Good nutrition from infancy through adolescence, with particular 
attention to adequate daily intake of calcium and vitamin D, is a key component in the attainment of maximum peak bone mass 
to prevent osteoporosis as highlighted by a number of studies. 
36
 Besides calcium and vitamin D, low vitamin K intake is also 
associated with low bone mineral density and increased osteoporotic fracture. It is possible that vitamin K indirectly affects the 
skeleton via control of renal calcium excretion.37-39 
Ensuring that the patient receives adequate calcium, vitamin D, and vitamin K is important in managing her osteoporosis. 
Analysis of the patient’s intake suggests that she meets recommended intake with current combination of foods, formula, and 
supplements. The supplements alone provide 100% calcium, 54% phosphorus, 400% vitamin D, and 60% vitamin K while food 
intake provides 9.6% calcium, 22% phosphorus, 14% vitamin D and 77% vitamin K of the recommended amounts. Although her 
diet is adequate in calcium, phosphorus, and vitamin D for bone health, DEXA scan is worsening through the past year. Few 
data exist to guide clinical care for children or premenopausal women who have low bone density (Z score less than or equal to 
-2.0) and/or fragility fractures. Regular weight bearing exercise and adequate calcium and vitamin D intake are the general rules 
in preventing further bone mineral loss. However, this patient has cerebral palsy with significantly increased muscle tone in 
lower extremities which limited exercise capacity. Dealing with osteoporosis was challenging in this particular situation, 
because she has multiple risk factors. In addition, the current Dietary Reference Intakes values were developed based on 
healthy American and Canadian population.  Her progressive worsening bone mineral density in regardless of adequate 
micronutrients intake poses the questions of whether DRI is an appropriate reference. New reference values based on children 
with epilepsy will be more appropriate to use in this case.  
Mother and grandmother are the main caregivers. They were informed of the risk and benefit of AEDs and KD, but they felt that 
the quality of life achieved since the introduction of KD outweighed the possible metabolic complications.  Both treatments 
were considered equally important and necessary to achieve optimal seizure control. Treatment goal is aimed to reach a 







The simultaneous use of KD and AEDs therapy appears to be clinically effective in this case. Dietary intake alone on KD is likely 
to increase risk of calcium and vitamin D deficiency. The use of dietary supplements plays an important part in meeting DRI. 
Alternative DRI for epilepsy children will be necessary to provide more accurate micronutrient reference. A safe balance 
between AEDs and KD with bone density can be challenging and requires close monitoring.  
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